124 related articles for article (PubMed ID: 27329811)
1. Nuclear cereblon modulates transcriptional activity of Ikaros and regulates its downstream target, enkephalin, in human neuroblastoma cells.
Wada T; Asahi T; Sawamura N
Biochem Biophys Res Commun; 2016 Aug; 477(3):388-94. PubMed ID: 27329811
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
[TBL] [Abstract][Full Text] [Related]
3. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP
Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790
[TBL] [Abstract][Full Text] [Related]
4. The interacting domains in cereblon differentially modulate the immunomodulatory drug-mediated ubiquitination and degradation of its binding partners.
Tao J; Yang J; Xu G
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):443-449. PubMed ID: 30458989
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB.
Solomon LA; Batista CR; DeKoter RP
Exp Hematol; 2017 Dec; 56():46-57.e1. PubMed ID: 28893618
[TBL] [Abstract][Full Text] [Related]
6. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
[TBL] [Abstract][Full Text] [Related]
7. [Thalidomide, cereblon and multiple myeloma].
Ogura T
Nihon Rinsho; 2015 Jan; 73(1):149-55. PubMed ID: 25626321
[TBL] [Abstract][Full Text] [Related]
8. Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL.
Hagner PR; Chiu H; Chopra VS; Colombo M; Patel N; Estevez MO; Waldman MF; Loos R; Towfic F; Gandhi AK
Clin Cancer Res; 2022 Aug; 28(15):3367-3377. PubMed ID: 35583604
[TBL] [Abstract][Full Text] [Related]
9. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
Matyskiela ME; Zhang W; Man HW; Muller G; Khambatta G; Baculi F; Hickman M; LeBrun L; Pagarigan B; Carmel G; Lu CC; Lu G; Riley M; Satoh Y; Schafer P; Daniel TO; Carmichael J; Cathers BE; Chamberlain PP
J Med Chem; 2018 Jan; 61(2):535-542. PubMed ID: 28425720
[TBL] [Abstract][Full Text] [Related]
10. Positive selection of cereblon modified function including its E3 ubiquitin ligase activity and binding efficiency with AMPK.
Onodera W; Asahi T; Sawamura N
Mol Phylogenet Evol; 2019 Jun; 135():78-85. PubMed ID: 30836149
[TBL] [Abstract][Full Text] [Related]
11. Cereblon is recruited to aggresome and shows cytoprotective effect against ubiquitin-proteasome system dysfunction.
Sawamura N; Wakabayashi S; Matsumoto K; Yamada H; Asahi T
Biochem Biophys Res Commun; 2015 Sep; 464(4):1054-1059. PubMed ID: 26188093
[TBL] [Abstract][Full Text] [Related]
12. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
Hagner PR; Man HW; Fontanillo C; Wang M; Couto S; Breider M; Bjorklund C; Havens CG; Lu G; Rychak E; Raymon H; Narla RK; Barnes L; Khambatta G; Chiu H; Kosek J; Kang J; Amantangelo MD; Waldman M; Lopez-Girona A; Cai T; Pourdehnad M; Trotter M; Daniel TO; Schafer PH; Klippel A; Thakurta A; Chopra R; Gandhi AK
Blood; 2015 Aug; 126(6):779-89. PubMed ID: 26002965
[TBL] [Abstract][Full Text] [Related]
13. De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives.
Heim C; Pliatsika D; Mousavizadeh F; Bär K; Hernandez Alvarez B; Giannis A; Hartmann MD
J Med Chem; 2019 Jul; 62(14):6615-6629. PubMed ID: 31251063
[TBL] [Abstract][Full Text] [Related]
14. Cereblon-mediated degradation of the amyloid precursor protein via the ubiquitin-proteasome pathway.
Kurihara T; Asahi T; Sawamura N
Biochem Biophys Res Commun; 2020 Mar; 524(1):236-241. PubMed ID: 31983437
[TBL] [Abstract][Full Text] [Related]
15. Rescue of Learning and Memory Deficits in the Human Nonsyndromic Intellectual Disability Cereblon Knock-Out Mouse Model by Targeting the AMP-Activated Protein Kinase-mTORC1 Translational Pathway.
Bavley CC; Rice RC; Fischer DK; Fakira AK; Byrne M; Kosovsky M; Rizzo BK; Del Prete D; Alaedini A; Morón JA; Higgins JJ; D'Adamio L; Rajadhyaksha AM
J Neurosci; 2018 Mar; 38(11):2780-2795. PubMed ID: 29459374
[TBL] [Abstract][Full Text] [Related]
16. IMiD compounds affect CD34
Li S; Fu J; Wang H; Ma H; Xu X; Yang YG; Deng S; Mapara MY; Lentzsch S
Blood Adv; 2018 Mar; 2(5):492-504. PubMed ID: 29496670
[TBL] [Abstract][Full Text] [Related]
17. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs.
Ito T; Handa H
Int J Hematol; 2016 Sep; 104(3):293-9. PubMed ID: 27460676
[TBL] [Abstract][Full Text] [Related]
18. Homo-PROTACs for the Chemical Knockdown of Cereblon.
Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
[TBL] [Abstract][Full Text] [Related]
19. Regulation of AMPK Activity by CRBN Is Independent of the Thalidomide-CRL4
Yang SJ; Jeon S; Baek JW; Lee KM; Park CS
Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34073624
[TBL] [Abstract][Full Text] [Related]
20. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
Petzold G; Fischer ES; Thomä NH
Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]